22 November 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Sofosbuvir with velpatasvir and voxilaprevir (Vosevi)
  
• Glecaprevir with pibrentasvir (Maviret)
  
• C1 esterase inhibitor (human) (Cinryze)
  
• Dexketoprofen with tramadol hydrochloride (Skudexum)
  
• Ribociclib succinate (Kisqali)
  
• Dabrafenib mesylate (Tafinlar)
  
• Trametinib dimethyl sulphoxide (Mekinist)
  
• Influenza vaccine (quadrivalent) (Influvac Tetra)
  
• Lacosamide (Vimpat)
  

Read TC agenda [French]